The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting for 13% of all deaths worldwide, resulting in 8.2 million deaths annually. The NEOSETAC project focuses on breast cancer, the most common cancer in women. It comprises of 10.4% of all the cancer incidences among women, causing more than 400.000 deaths worldwide per year.

In Europe, there is more than twice of the amount of new breast cancer cases annually than anywhere else in the world. The complexity of breast cancer makes it a big challenge for successful treatment.


The NEOSETAC project will demonstrate the therapeutic anti-cancer potential of a novel Selenium-based therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer treatment so far has been limited to chemoprevention as dietary supplement. NEOSETAC aimS to improve the therapeutic window, pharmacokinetic properties, and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se compounds at desired locations (tumor lesions and metastasis) is achieved. Furthermore, NPs are functionalized by cancer cell / cancer stem cell targeting ligands, to further improve the therapeutic efficacy, and to prevent cancer recurrence after chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover, targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.

ADSI provides know-how in the designing of preclinical studies.

Total volume: 504,000.- Euro (ADSI share 36,000.- Euro)
Duration: 01/2018 – 12/2022

Sei kein Gefangener der Vergangenheit:
Internet Explorer ist für unsere Technologie zu alt!
Bitte verwende einen der folgenden Browser!